MedTrace Logo

A Study of JNJ-79032421 Targeting Mesothelin for Advanced Stage Solid Tumors

NCT06255665 · Status: COMPLETED · Phase: PHASE1 · Type: INTERVENTIONAL · Enrollment: 35

Last updated 2025-07-20

No results posted yet for this study

Summary

The purpose of this study is to determine recommended phase 2 dose(s) (RP2Ds) of JNJ-79032421 and to determine the safety and tolerability of JNJ-79032421 at the RP2D(s).

Conditions

  • Advanced Stage Solid Tumors

Interventions

DRUG

JNJ-79032421

JNJ-79032421 will be administered.

DRUG

JNJ-79032421

JNJ-79032421 will be administered at RP2D regimen.

Sponsors & Collaborators

  • Janssen Research & Development, LLC

    lead INDUSTRY

Principal Investigators

  • Janssen Research & Development, LLC Clinical Trial · Janssen Research & Development, LLC

Study Design

Allocation
NA
Purpose
TREATMENT
Masking
NONE
Model
SEQUENTIAL

Eligibility

Min Age
18 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2024-02-09
Primary Completion
2025-06-23
Completion
2025-06-23
FDA Drug
Yes

Countries

  • Spain

Study Locations

More Related Trials

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT06255665 on ClinicalTrials.gov